.Pharmacolibrary.Drugs.C_CardiovascularSystem.C02K_OtherAntihypertensives.C02KX54_MacitentanAndTadalafil.MacitentanAndTadalafil .Pharmacolibrary.Drugs.C_CardiovascularSystem.C02K_OtherAntihypertensives.C02KX54_MacitentanAndTadalafil.MacitentanAndTadalafil| name: | MacitentanAndTadalafil | |
| ATC code: | C02KX54 | route: | oral |
| compartments: | 2 | |
| dosage: | 10 | mg |
| volume of distribution: | 50 | L |
| clearance: | 5 | L/h |
| other parameters in model implementation | ||
Macitentan and tadalafil is a fixed-dose combination medication indicated for the treatment of pulmonary arterial hypertension (PAH) to reduce morbidity. Macitentan is an endothelin receptor antagonist, and tadalafil is a phosphodiesterase type 5 inhibitor. This combination is approved in several regions for PAH management.
Population pharmacokinetic estimates for healthy adults. No published pharmacokinetic models with joint parameter estimates for the fixed-dose combination are currently available; parameters are estimated based on models for separate agents.